CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. As the demand for healthcare increases at a rapid rate, so does the opportunity for companies to invest and pioneer new technologies to improve the quality of care for individuals suffering from numerous diseases and ailments. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (PHGRF) (PHGI), OHR Pharmaceuticals, Inc. (NASDAQ: OHRP), Valeritas Holdings, Inc. (NASDAQ: VLRX), and Kitov Pharmaceutical Holdings, Ltd. (NASDAQ: KTOV) are 4 healthcare stocks worth looking into on Thursday.
Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Wednesday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share. Over the course of the past thirty days, Premier has seen a period of bullish trading as its shared climbed over 30% this past month. The Company has seen significant growth in the month of December following momentum gained from several key announcements regarding two separate LOI agreements.
Earlier in December, Premier Health Group (PHGRF) (PHGI) announced that, in an effort to advance its overarching strategy to cover all major verticals associated with primary care as well as develop innovative approaches that combine human skill-based expertise with emerging technologies, it had signed a binding LOI to acquire all outstanding securities of Cloud Practice Inc.
Presently, Cloud Practice offers cloud-based electronic medal records software for medical professionals across Canada. As stated in their recent financial reports, Cloud Practice is EBITDA positive, resulting in immediate cash flow generation and earnings accretion for Premier Health.
Dr. Essam Hamza, CEO of Premier Health Group (PHGRF) (PHGI), said, ''We are ecstatic at the opportunity to build on our patient-centric technology platform through the integration of Cloud Practice’s suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking, and other premium services with our electronic medical record (EMR) system.''
OHR Pharmaceuticals, Inc. (OHRP) may see its shares enjoy significant gains on Thursday as the Company announced today that it has entered into a definitive merger agreement with NeuBase Therapeutics, Inc., under which the stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will effectively create a public company focused on advancing NeuBase's treatment technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.
Jason Slakter, M.D., Chief Executive Officer of OHR Pharmaceutical, said, ''We are excited to enter into a definitive merger agreement with NeuBase, a company with powerful technology and pipeline that has the potential to address multiple unmet medical needs across a range of serious genetic diseases. The proposed merger will provide an opportunity to create value as an innovative, science-driven company with a proprietary technology platform utilizing advanced gene silencing techniques.''
Valeritas Holdings, Inc. (VLRX), a medical tech company and proud maker of V-Go® Wearable Insulin Delivery device, announced on Thursday that Humana, one of the nation's leading health and well-being companies in the US, has given V-Go Preferred status on Humana's Part D formularies.
In a press release regarding the announcement, John Timberlake, CEO of Valeritas, said, "We are very excited that V-Go is now Preferred on Humana's Medicare formularies, which will improve patient access to V-Go at an affordable monthly copay for its members with type 2 diabetes.''
Kitov Pharmaceutical Holdings, Ltd. (KTOV), an innovative biopharmaceutical company, announced at the tail-end of September that Hadas Reuven, Chief Technology Officer at the Company's subsidiary, TyrNovo Ltd, would present pre-clinical data on NT219, one of their new anti-tumor resistance drug treatments, in a session at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival later in 2018.
At the time of the announcement, Dr. Reuveni commented, "We are pleased to have been chosen to present an abstract at the upcoming AACR meeting. These very exciting data, which we had also presented at a cancer conference earlier this year, hold great promise for mobilizing the patient's immune system against tumors. In the future, tumors in patients who have functional immune systems may respond to NT219 both by blocking feedback pathways, overcoming drug resistance, and by removing the 'protective shield' from the tumor, allowing an anti-tumor immune attack.''
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone who wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC., which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC., an affiliate of JSG COMMUNICATIONS, LLC., and Premier Health Group, Inc. we were hired for a period from 10/1/2018-4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for and were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group, Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.